| Medical and Health Sciences | Lifetime | 762 | GB 84 | 99.97 |
| Medical and Health Sciences | 2021-2025 | 300 | GB 32 | 99.94 |
| Rheumatology | Lifetime | 10 | GB 2 | 99.94 |
| Immunology | Lifetime | 105 | GB 8 | 99.81 |
| Hematology | Lifetime | 92 | GB 4 | 99.48 |
| Rheumatology | 2021-2025 | 2 | GB 1 | 99.92 |
| Immunology | 2021-2025 | 21 | GB 1 | 99.52 |
| Hematology | 2021-2025 | 63 | GB 5 | 98.64 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 3 | GB 2 | 99.96 |
| Rheumatoid Arthritis Research and Therapies | Lifetime | 7 | GB 2 | 99.93 |
| Systemic Lupus Erythematosus Research | Lifetime | 12 | GB 2 | 99.87 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 25 | GB 3 | 99.75 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 14 | GB 3 | 99.82 |
| Spondyloarthritis Studies and Treatments | Lifetime | 9 | GB 2 | 99.86 |
| Inflammasome and immune disorders | Lifetime | 39 | GB 4 | 99.42 |
| Immune Cell Function and Interaction | Lifetime | 614 | GB 48 | 99.21 |
| Toxin Mechanisms and Immunotoxins | Lifetime | 165 | GB 7 | 98.13 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 779 | GB 73 | 98.75 |
| IL-33, ST2, and ILC Pathways | Lifetime | 189 | GB 19 | 98.12 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 693 | GB 48 | 98.28 |
| Dermatology and Skin Diseases | Lifetime | 420 | GB 46 | 97.92 |
| Long-Term Effects of COVID-19 | Lifetime | 929 | GB 101 | 94.39 |
| Biosimilars and Bioanalytical Methods | Lifetime | 285 | GB 21 | 95.26 |
| Viral Infections and Immunology Research | Lifetime | 999 | GB 94 | 95.74 |
| Tendon Structure and Treatment | Lifetime | 992 | GB 74 | 94.30 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 1 | GB 1 | 99.96 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 3 | GB 1 | 99.90 |
| Spondyloarthritis Studies and Treatments | 2021-2025 | 4 | GB 1 | 99.85 |
| Psoriasis: Treatment and Pathogenesis | 2021-2025 | 9 | GB 1 | 99.74 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 63 | GB 7 | 98.66 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 18 | GB 1 | 97.06 |
| Dermatology and Skin Diseases | 2021-2025 | 646 | GB 44 | 90.65 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 532 | GB 35 | 81.51 |
| Peripheral Neuropathies and Disorders | 2021-2025 | 817 | GB 51 | 81.76 |
| Cell Adhesion Molecules Research | 2021-2025 | 781 | GB 48 | 71.27 |
| Musculoskeletal Disorders and Rehabilitation | 2021-2025 | 557 | GB 76 | 54.68 |
